文献速递姑息放疗与转移瘤放疗物理与技术

立体定向体部放疗治疗寡转移性骨转移的疗效与毒性的前瞻性研究

A Prospective Study Assessing the Efficacy and Toxicity of Stereotactic Body Radiation Therapy for Oligometastatic Bone Metastases.
PubMed 文献 · Adv Radiat Oncol · 2023-12-06

这项前瞻性II期试验纳入98例寡转移性骨病患者(≤3个活动病灶),于2016年12月至2019年5月在布莱根妇女医院/达纳法伯癌症中心及贝斯以色列女执事医疗中心接受立体定向体部放疗(SBRT),剂量分割方案未由方案强制规定。中位随访26.7个月,2年局部无进展生存率84.8%,2年无进展生存率47.5%,2年总生存率87.3%;26例(26.5%)出现治疗相关毒性。作者认为SBRT有效且可耐受。

要点

  • 98例患者共126个病灶接受SBRT,最常见组织学为前列腺癌(68.4%,67/98)。
  • 2年局部无进展生存率84.8%,2年无进展生存率47.5%,2年总生存率87.3%。
  • 26例(26.5%,26/98)发生治疗相关毒性,4例(4.1%,4/98)出现局部进展。

核心结论

  • 作者认为该研究支持现有文献,显示SBRT对寡转移性骨病患者有效且可耐受。
  • 作者认为有必要且合理开展更大规模的III期试验以确定长期疗效和毒性。

研究设计与样本

  • 前瞻性II期试验,纳入寡转移性骨病(定义为≤3个活动病灶)且既往未接受放疗的患者。
  • 患者于2016年12月至2019年5月在布莱根妇女医院/达纳法伯癌症中心及贝斯以色列女执事医疗中心接受SBRT。
  • SBRT剂量和分割方案未由方案强制规定。
  • 共纳入98例患者和126个病灶,组织学来源多样。

主要发现

  • 中位年龄72.8岁(80.6%男性,19.4%女性),中位随访26.7个月。
  • 最常见组织学为前列腺癌(68.4%,67/98)。
  • 最常见剂量处方为27/30 Gy分3次(27.0%,34/126)、30 Gy分5次(16.7%,21/126)或30/35 Gy分5次(16.7%,21/126)。
  • 4例患者(4.1%,4/98)出现局部进展,每例1个部位(3.2%,4/126)。
  • 2年局部无进展生存率(包括无局部进展的死亡)84.8%,2年无进展生存率(包括死亡及局部、远处和前列腺特异性抗原进展)47.5%,2年总生存率87.3%。

关键数值与推荐

  • 寡转移性骨病定义为≤3个活动病灶。
  • 多种剂量方案反映剂量绘画,即临床靶区接受较低剂量、大体肿瘤体积接受较高剂量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为有必要且合理开展更大规模的III期试验以确定长期疗效和毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) is a promising treatment for oligometastatic disease in bone because of its delivery of high dose to target tissue and minimal dose to surrounding tissue. The purpose of this study is to assess the efficacy and toxicity of this treatment in patients with previously unirradiated oligometastatic bony disease. METHODS AND MATERIALS: In this prospective phase II trial, patients with oligometastatic bone disease, defined as ≤3 active sites of disease, were treated with SBRT at Brigham and Women's Hospital/Dana Farber Cancer Center and Beth Israel Deaconess Medical Center between December 2016 and May 2019. SBRT dose and fractionation regimen were not protocol mandated. Local progression-free survival, progression-free survival, prostatic specific antigen progression, and overall survival were reported. Treatment-related toxicity was also reported. RESULTS: A total of 98 patients and 126 lesions arising from various tumor histologies were included in this study. The median age of patients enrolled was 72.8 years (80.6% male, 19.4% female). Median follow-up was 26.7 months. The most common histology was prostate cancer (68.4%, 67/98). The most common dose prescriptions were 27/30 Gy in 3 fractions (27.0%, 34/126), 30 Gy in 5 fractions (16.7%, 21/126), or 30/35 Gy in 5 fractions (16.7%, 21/126). Multiple doses per treatment regimen reflect dose painting employing the lower dose to the clinical target volume and higher dose to the gross tumor volume. Four patients (4.1%, 4/98) experienced local progression at 1 site for each patient (3.2%, 4/126). Among the entire cohort, 2-year local progression-free survival (including death without local progression) was 84.8%, 2-year progression-free survival (including deaths as well as local, distant, and prostatic specific antigen progression) was 47.5%, and 2-year overall survival was 87.3%. Twenty-six patients (26.5%, 26/98) developed treatment-related toxicities. CONCLUSIONS: Our study supports existing literature in showing that SBRT is effective and tolerable in patients with oligometastatic bone disease. Larger phase III trials are necessary and reasonable to determine long-term efficacy and toxicities.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lee JH, Shi DD, Shin KY, et al. A Prospective Study Assessing the Efficacy and Toxicity of Stereotactic Body Radiation Therapy for Oligometastatic Bone Metastases. Adv Radiat Oncol. 2023. PMID: 38406391. doi:10.1016/j.adro.2023.101411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。